Newsroom | 5009 results

ATLANTA--(BUSINESS WIRE)--Georgia ProtonCare Center Inc. (“GPCC” or “the Company”) announced today that it has entered into an asset purchase agreement with Emory University, by and on behalf of Emory University Hospital Midtown (“Emory”) to purchase substantially all of its assets plus the assumption of certain liabilities. GPCC’s main asset is a proton therapy cancer treatment center (the “Facility”) located in Midtown, Atlanta. Emory clinicians provide the day-to-day care and treatment for p...

NEW YORK--(BUSINESS WIRE)--Qure.ai secures major global health grant to build AI-powered point-of-care ultrasound...

ATLANTA--(BUSINESS WIRE)--Axion BioSystems, a leading life sciences tools company focused on cutting-edge live-cell bioelectronic assay and imaging systems, announces the acquisition of the intellectual property and assets of CytoTronics, Inc. The purchase brings novel high-density (HD) electrode array technology developed at Harvard University to Axion’s growing product suite and strengthens Axion’s ability to provide researchers with the most advanced tools for disease research and drug disco...

HAYWARD, Calif.--(BUSINESS WIRE)--Medicare Administrator Contractors, Novitas and FCSO, have assigned payment rates for SCINTIX autonomous radiotherapy in freestanding cancer centers....

IRVING, Texas--(BUSINESS WIRE)--The 2026 Vizient state of the industry report highlights structural pressure, financial risk and opportunities for resilience....

ATLANTA & IRVINE, Calif.--(BUSINESS WIRE)--Stance Health Solutions selects MediStreams to automate its explanation of benefits (EOB) conversion processes, accelerating cash posting....

IRVINE, California y ÁMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., líder en oncología de precisión para el cáncer de mama, anunció hoy que la actualización de las Guías de Práctica Clínica en Oncología de la NCCN1 (NCCN Guidelines®) reconoce que MammaPrint® + BluePrint ® pueden ayudar a identificar un subgrupo de pacientes con cáncer de mama en estadio temprano (EBC), con receptores hormonales positivos y HER2 negativo (HR+/HER2–), que tienen mayor probabilidad de beneficiarse de quimioterapia bas...

IRVINE, Calif. e AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., azienda leader nell'oncologia di precisione per il carcinoma mammario, oggi ha annunciato che le Linee guida cliniche aggiornate del NCCN in oncologia1 (NCCN Guidelines® ) ora riconoscono che MammaPrint ® + BluePrint ® può aiutare a identificare un sottogruppo di pazienti affetti da tumore della mammella iniziale (EBC), positivo al recettore ormonale, negativo all'HER2 (HR+/HER2–) che potrebbero trarre maggior beneficio dalla chemioter...

IRVINE, Californie et AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., leader dans le domaine de l’oncologie de précision pour le cancer du sein, a annoncé aujourd’hui que les directives cliniques mises à jour du NCCN en oncologie1 (NCCN Guidelines® ) reconnaissent désormais que MammaPrint® + BluePrint® peuvent aider à identifier un sous-groupe de patientes atteintes d’un cancer du sein précoce (EBC) à récepteurs hormonaux positifs et HER2 négatifs (HR+/HER2–) qui sont les plus susceptibles de bénéfi...

IRVINE, Calif. en AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., een leider op het gebied van precisie-oncologie voor borstkanker, heeft vandaag bekendgemaakt dat de bijgewerkte NCCN Clinical Practice Guidelines in Oncology1 (NCCN Guidelines® ) nu erkennen dat MammaPrint® + BluePrint® kunnen helpen bij het identificeren van een subgroep van hormoonreceptorpositieve, HER2-negatieve (HR+/HER2–) patiënten met borstkanker in een vroeg stadium (EBC) die het meest waarschijnlijk baat hebben bij chemother...